Roundview Capital LLC decreased its stake in shares of DaVita HealthCare Partners Inc. (NYSE:DVA) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,503 shares of the company’s stock after selling 250 shares during the period. Roundview Capital LLC’s holdings in DaVita HealthCare Partners were worth $353,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Calvert Investment Management Inc. raised its stake in DaVita HealthCare Partners by 0.6% in the second quarter. Calvert Investment Management Inc. now owns 10,300 shares of the company’s stock valued at $796,000 after buying an additional 57 shares in the last quarter. FDx Advisors Inc. raised its stake in DaVita HealthCare Partners by 0.6% in the second quarter. FDx Advisors Inc. now owns 23,743 shares of the company’s stock valued at $1,836,000 after buying an additional 134 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its stake in DaVita HealthCare Partners by 0.5% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 52,796 shares of the company’s stock valued at $4,082,000 after buying an additional 246 shares in the last quarter. Cacti Asset Management LLC raised its stake in DaVita HealthCare Partners by 6.3% in the third quarter. Cacti Asset Management LLC now owns 4,305 shares of the company’s stock valued at $280,000 after buying an additional 255 shares in the last quarter. Finally, Mycio Wealth Partners LLC raised its stake in DaVita HealthCare Partners by 1.4% in the second quarter. Mycio Wealth Partners LLC now owns 23,790 shares of the company’s stock valued at $1,839,000 after buying an additional 324 shares in the last quarter. Institutional investors own 85.31% of the company’s stock.

Institutional Ownership by Quarter for DaVita HealthCare Partners (NYSE:DVA)

DaVita HealthCare Partners Inc. (NYSE:DVA) traded down 0.29% during midday trading on Thursday, reaching $64.66. The company’s stock had a trading volume of 1,072,387 shares. DaVita HealthCare Partners Inc. has a 12-month low of $54.50 and a 12-month high of $78.77. The firm has a 50 day moving average price of $64.32 and a 200-day moving average price of $64.30. The company has a market cap of $12.76 billion, a P/E ratio of 18.85 and a beta of 1.02.

DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 16th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.07. DaVita HealthCare Partners had a return on equity of 16.16% and a net margin of 4.92%. The firm had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.74 billion. During the same period in the prior year, the business posted $1.12 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities research analysts predict that DaVita HealthCare Partners Inc. will post $3.76 earnings per share for the current fiscal year.

“Roundview Capital LLC Lowers Position in DaVita HealthCare Partners Inc. (DVA)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The original version of this story can be read at http://www.dailypolitical.com/2017/02/16/roundview-capital-llc-lowers-position-in-davita-healthcare-partners-inc-dva.html.

Several research firms recently weighed in on DVA. Robert W. Baird lowered DaVita HealthCare Partners from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $68.00 to $69.00 in a research report on Tuesday, December 13th. Jefferies Group LLC restated a “buy” rating and set a $70.00 price target (down from $86.00) on shares of DaVita HealthCare Partners in a research report on Saturday, November 19th. Zacks Investment Research lowered DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, January 31st. Bank of America Corporation restated a “hold” rating and set a $68.00 price target on shares of DaVita HealthCare Partners in a research report on Monday, November 21st. Finally, Wells Fargo & Company restated an “outperform” rating on shares of DaVita HealthCare Partners in a research report on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. DaVita HealthCare Partners currently has an average rating of “Hold” and a consensus price target of $72.82.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives.

5 Day Chart for NYSE:DVA

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita HealthCare Partners Inc. (NYSE:DVA).

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.